Atea Pharmaceuticals Inc

AVIR

NASDAQ. Currency in USD

4.38 -0.23 ( -4.99% )

Real time prices: December 19

Market Cap.
364.80M
Beta (5Y monthly)
0.24
Price/Earnings
12.83
EPS (TTM)
0.35
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
733,620
1y Target Est.
9.00
Day's Range
4.30
-
4.55
52 Week's Range
4.30
-
9.79

Historical Summary

Performance
EPS growth
Share Buybacks

About Atea Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://ateapharma.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
83.10M
Employees
68
Address
125 Summer Street, Boston, MA, United States, 02110
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Latest news

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High...
By GlobeNewswire Inc. - 9 weeks ago

Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage...
By GlobeNewswire Inc. - 10 weeks ago

Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade

Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing...
By Zacks Investment Research - 12 weeks ago

After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)

The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is...
By Zacks Investment Research - 12 weeks ago

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with...
By GlobeNewswire Inc. - 12 weeks ago

Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat...
By Zacks Investment Research - 13 weeks ago

Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on...
By Zacks Investment Research - 13 weeks ago

Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall...
By Zacks Investment Research - 13 weeks ago